US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Astellas Pharma, Inc.

9.36

0.0000

Volume:- -

Turnover:- -

Market Cap:17.42B

PE:125.87

High:9.36

Open:9.36

Low:9.36

Close:9.36

Loading ...

Overview Company News Filings

Morgan Stanley Sticks to Its Hold Rating for Astellas Pharma (ALPMF)

Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresses

Astellas Pharma (ALPMY) Upgraded to Strong Buy: What Does It Mean for the Stock?

J.P. Morgan Remains a Hold on Astellas Pharma (ALPMF)

Astellas and YASKAWA Agree to Establish a Joint Venture Focused on Cell Therapy Manufacturing

Astellas and MBC BioLabs Announce the Sixth Annual Astellas Future Innovator Prize

U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo

Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)

Astellas Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in Japan

Astellas Makes Announcement about Management Structure

Bernstein Remains a Buy on Astellas Pharma (ALPMF)

Jefferies Reaffirms Their Hold Rating on Astellas Pharma (ALPMF)

Bernstein Sticks to Their Buy Rating for Astellas Pharma (ALPMF)

U.S. FDA Confirms Class 1 Resubmission of the Supplemental New Drug Application for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

China's National Medical Products Administration (NMPA) Approves PADCEV™ in combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Bladder Cancer

Astellas and Dr. Jen Ashton launch "Cooler Moments" to Spotlight Menopausal Hot Flashes and Empower Women to Advocate for Themselves

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ALPMF/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALPMF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALPMF\",,,,,undefined,":{"symbol":"ALPMF","market":"US","secType":"STK","nameCN":"Astellas Pharma, Inc.","latestPrice":9.3585,"timestamp":1748894400000,"preClose":9.3585,"halted":0,"volume":0,"delay":15,"floatShares":1731101601,"shares":1861787075,"eps":0.074352,"marketStatus":"Closed","change":0,"latestTime":"06-02 16:00:00 EDT Delay","open":9.3585,"high":9.3585,"low":9.3585,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":0.074352,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1748937600000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"PINK LIMITED","adjPreClose":9.3585,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALPMF\",,,,,undefined,":{"symbol":"ALPMF","floatShares":1731101601,"roa":"4.21%","roe":"3.26%","lyrEps":0.062841,"shares":1861787075,"dividePrice":0.518518,"high":9.3585,"amplitude":0,"preClose":9.3585,"low":9.3585,"week52Low":8.405,"pbRate":"1.64","psRate":"1.30","week52High":12.74,"institutionHeld":0,"latestPrice":9.3585,"eps":0.074352,"divideRate":0.055406,"volume":0,"delay":15,"ttmEps":0.074352,"open":9.3585,"prevYearClose":9.86,"prevWeekClose":9.3585,"prevMonthClose":9.3585,"prevQuarterClose":9.75,"fiveDayClose":9.55,"twentyDayClose":10.12,"sixtyDayClose":9.7951},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALPMF\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540784331","title":"Morgan Stanley Sticks to Its Hold Rating for Astellas Pharma (ALPMF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2540784331","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540784331?lang=en_us&edition=fundamental","pubTime":"2025-06-01 00:55","pubTimestamp":1748710517,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Shinichiro Muraoka from Morgan Stanley maintained a Hold rating on Astellas Pharma (ALPMF – Research Report), with ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanley-sticks-to-its-hold-rating-for-astellas-pharma-alpmf-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanley-sticks-to-its-hold-rating-for-astellas-pharma-alpmf-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALPMF"],"gpt_icon":0},{"id":"2532607777","title":"Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresses","url":"https://stock-news.laohu8.com/highlight/detail?id=2532607777","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532607777?lang=en_us&edition=fundamental","pubTime":"2025-05-01 21:00","pubTimestamp":1746104400,"startTime":"0","endTime":"0","summary":"ARVO andRWC abstracts feature analyses on biomarkers, mechanism of disease, patient experience and other data fromIZERVAY pivotal studies. TOKYO, May 1, 2025 /PRNewswire/ -- Astellas Pharma Inc. , maker of IZERVAY, a C5 inhibitor for the treatment of geographic atrophy *, will highlight new data that enhances continued understanding of the science of GA, and the experience of patients living with the progressive disease at the Association for Research in Vision and Ophthalmology Annual Meeting , May 4-8, Salt Lake City, Utah, and Retina World Congress , May 8-11, Fort Lauderdale, Florida.The data comprises nine abstracts, including two oral presentations, featuring analyses on biomarkers, patient experience, mechanism of disease and other insights from the GATHER Phase 3 studies ofIZERVAY for the treatment of GA secondary to age-related macular degeneration .Marci English, Senior Vice President, Biopharma and Ophthalmology Development, Astellas Pharma\"Recognizing the early indicators a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/astellas-present-data-geographic-atrophy-130000768.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astellas-present-data-geographic-atrophy-130000768.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4573","LU0081259029.USD","IE0009356076.USD","LU1989764664.SGD","BK4605","LU1923623000.USD","LU0109392836.USD","LU0889565833.HKD","LU1303367103.USD","LU0127658192.USD","LU1242518857.USD","LU1880398554.USD","LU2458330243.SGD","BK4614","LU2098885051.SGD","LU2250418816.HKD","LU0823421416.USD","LU0642271901.SGD","BK4588","IE00BMPRXR70.SGD","LU1803068979.SGD","ACP","ALPMY","BK4529","ALPMF","LU1316542783.SGD","BK4512","LU1951198990.SGD","LU0390134368.USD","BK4534","IE0004445239.USD","LU0082616367.USD","LU0823421333.USD","GFS","LU0719512351.SGD","BK4543","LU2054465674.USD","LU2264538146.SGD","BK4141","RWC","LU1988902786.USD","BK4575","LU0198837287.USD","IE00B5949003.HKD","LU1242518931.SGD","LU2458330169.SGD","IE00BMPRXN33.USD","LU1852331112.SGD","BK4007","LU1951200564.SGD"],"gpt_icon":1},{"id":"2531640807","title":"Astellas Pharma (ALPMY) Upgraded to Strong Buy: What Does It Mean for the Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2531640807","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531640807?lang=en_us&edition=fundamental","pubTime":"2025-04-30 00:00","pubTimestamp":1745942410,"startTime":"0","endTime":"0","summary":"Astellas Pharma Inc.  could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 . This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.Therefore, the Zacks rating upgrade for Astellas Pharma basically reflects positivity about its earnings outlook that could translate into buying pressure and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astellas-pharma-alpmy-upgraded-strong-160010586.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALPMF","ALPMY"],"gpt_icon":0},{"id":"2517544503","title":"J.P. Morgan Remains a Hold on Astellas Pharma (ALPMF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517544503","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517544503?lang=en_us&edition=fundamental","pubTime":"2025-03-08 20:06","pubTimestamp":1741435619,"startTime":"0","endTime":"0","summary":"In a report released on March 5, Seiji Wakao from J.P. Morgan maintained a Hold rating on Astellas Pharma (ALPMF – Research Report), with a price t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-remains-a-hold-on-astellas-pharma-alpmf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-remains-a-hold-on-astellas-pharma-alpmf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0225283273.USD","LU2089284900.SGD","LU2089283258.USD","BK4504","LU0267386448.USD","LU2023251221.USD","LU1989772840.SGD","LU1548497426.USD","LU0158827948.USD","LU1074936037.SGD","LU0098860793.USD","LU2111349929.HKD","BK4007","LU2357305700.SGD","LU2028103732.USD","LU1732800096.USD","LU1363072403.SGD","BK4516","LU0106261372.USD","LU0320765646.SGD","BK4127","IE00BKVL7J92.USD","LU0006306889.USD","LU1989772923.USD","LU0795875086.SGD","BK4585","IE00BZ1G4Q59.USD","LU1162221912.USD","LU1720051017.SGD","BK4534","LU0106831901.USD","LU1720051108.HKD","LU0912757837.SGD","LU0314104364.USD","BK4581","LU2271345857.HKD","ALPMF","LU1732799900.SGD","BK4588","LU1668664300.SGD","LU0795875169.SGD","LU2133065610.SGD","LU0158827781.USD","LU0971096721.USD","LU2347655156.SGD"],"gpt_icon":0},{"id":"2517980901","title":"Astellas and YASKAWA Agree to Establish a Joint Venture Focused on Cell Therapy Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2517980901","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517980901?lang=en_us&edition=fundamental","pubTime":"2025-03-06 12:02","pubTimestamp":1741233720,"startTime":"0","endTime":"0","summary":"- Joint venture will aim to develop a cell therapy manufacturing platform through robotics and will offer access to startups and academic institutions -. TOKYO, March 5, 2025 /PRNewswire/ -- Astellas Pharma Inc.  and YASKAWA Electric Corporation  signed a definitive agreement to establish a joint venture for the development of a cell therapy product manufacturing platform utilizing the dual-arm robot \"Maholo.\" In addition, the joint venture will offer platform access to startups and academic institutions, fostering collaboration and innovation in the field of cell therapy.The planned joint venture will leverage Astellas' expertise in R&D and manufacturing for cell therapy and the dual arm robot \"Maholo,\" developed by YASKAWA's subsidiary, Robotic Biology Institute. The closing and establishment of the joint venture company are subject to certain closing conditions, including receipt of required regulatory approvals.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/astellas-yaskawa-agree-establish-joint-040200778.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astellas-yaskawa-agree-establish-joint-040200778.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALPMF","ADC","JYNT","YASKY","BK4080","YASKF","BK4161","BK4231","ALPMY","BK4185"],"gpt_icon":0},{"id":"2514894973","title":"Astellas and MBC BioLabs Announce the Sixth Annual Astellas Future Innovator Prize","url":"https://stock-news.laohu8.com/highlight/detail?id=2514894973","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514894973?lang=en_us&edition=fundamental","pubTime":"2025-02-27 23:00","pubTimestamp":1740668400,"startTime":"0","endTime":"0","summary":"Awardees win a year of access to a prestigious life-science incubator in San Francisco and toAstellas expertise to further their research. Award helps biotech start-ups accelerate early drug discovery and research efforts. NORTHBROOK, Ill., Feb. 27, 2025 /PRNewswire/ -- Astellas Pharma U.S. Inc. , and MBC BioLabs, a premier launchpad for early-stage life-science companies, today announced their collaboration on the Astellas Future Innovator Prize. The competition offers entrepreneurial scientists and emerging biotechnology start-ups one year's priority usage of MBC BioLabs' state-of-the-art Bay Area facilities and access to Astellas' research and development capabilities and business leaders.Entrepreneurial scientists, emerging life-science and biotechnology start-ups have until April 1, 2025 to enter the Astellas Future Innovator Prize by submitting their non-confidential company presentation, including a one-page executive summary here.Companies awarded an Astellas Future Innovator P","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/astellas-mbc-biolabs-announce-sixth-150000583.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astellas-mbc-biolabs-announce-sixth-150000583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","ALPMY","MBC","ALPMF","BK4086"],"gpt_icon":0},{"id":"2511532511","title":"U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2511532511","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511532511?lang=en_us&edition=fundamental","pubTime":"2025-02-13 07:32","pubTimestamp":1739403120,"startTime":"0","endTime":"0","summary":"TOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc.  today announced the U.S. Food and Drug Administration  approved expanded U.S. Prescribing information for IZERVAY  for the treatment of geographic atrophy  secondary to age-related macular degeneration . As a result, IZERVAY is now approved without a limitation on duration of dosing—providing physicians and patients with greater flexibility when managing GA.The approval follows Astellas' resubmission of the supplemental New Drug Application  for IZERVAY on December 26, 2024, within days of meeting with the FDA to clarify the Agency's feedback provided in the Complete Response Letter  issued in November 2024.Marci English, Senior Vice President, Biopharma and Ophthalmology Development, Astellas Pharma\"We are pleased with the FDA's decision to extend the use of IZERVAY for longer-term administration—further solidifying IZERVAY's status as a trusted choice for thousands of GA patients since its launch in 2023. To date, IZERVAY rem","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/u-fda-approves-expanded-label-233200789.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/u-fda-approves-expanded-label-233200789.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALPMF","LU2458330243.SGD","LU1880398554.USD","BK4605","LU1803068979.SGD","IE00B5949003.HKD","BK4530","LU0127658192.USD","LU0390134368.USD","IE0009356076.USD","IE0004445239.USD","CRL","LU0823421416.USD","BK4532","BK4543","BK4573","LU0109392836.USD","LU0823434740.USD","LU0889565833.HKD","IE00BMPRXR70.SGD","IE00BMPRXN33.USD","BK4141","LU2360106780.USD","LU2054465674.USD","BK4585","ALPMY","LU0823434583.USD","LU0823421333.USD","LU1064131342.USD","LU1242518857.USD","BK4554","LU1988902786.USD","BK4529","LU1852331112.SGD","LU1880398471.USD","LU1951200564.SGD","ACP","LU0082616367.USD","LU1923623000.USD","LU2264538146.SGD","GFS","LU0056508442.USD","LU1316542783.SGD","LU2250418816.HKD","BK4007","BK4566","BK4121","BK4534","LU1303367103.USD","LU0081259029.USD"],"gpt_icon":1},{"id":"2510356549","title":"Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo","url":"https://stock-news.laohu8.com/highlight/detail?id=2510356549","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510356549?lang=en_us&edition=fundamental","pubTime":"2025-02-12 03:13","pubTimestamp":1739301234,"startTime":"0","endTime":"0","summary":"On Monday, Pfizer Inc. and Astellas Pharma Inc.   released additional follow-up results from the Phase 3 EV-302 trial  of Padcev plus Keytruda  in patients with previously untreated locally advanced or metastatic urothelial cancer .Also Read: Pfizer Q4 Earnings: Revenue And EPS Beat, Seagen And COVID-19 Products Show Strength, Issues Strong FY25 Outlook. The results showed a sustained overall survival  and progression-free survival  benefit consistent with the findings of the primary analysis after an additional 12 months of follow-up .Results showed enfortumab vedotin plus pembrolizumab reduced the risk of death by 49% versus chemotherapy.The median OS was 33.8 months for the combination versus 15.9 months for chemotherapy.The OS benefit was observed in all prespecified subgroups, including cisplatin eligible and ineligible subgroups.The median PFS was 12.5 months for the combination versus 6.3 months for chemotherapy.In addition to longer follow-up data, an exploratory analysis evalu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-astellas-tout-encouraging-data-191354087.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0225771236.USD","LU0456855351.SGD","IE0002270589.USD","MRK","LU1894683348.USD","LU1057294990.SGD","ALPMY","ALPMF","BK4588","BK4211","IE00B19Z3581.USD","IE00B19Z3B42.SGD","SG9999013999.USD","BK4550","LU0289739699.SGD","OS","LU0321505439.SGD","PFE","SG9999001176.USD","PFS","BK4534","SG9999003800.SGD","LU0306807586.USD","SG9999002232.USD","IE000M9KFDE8.USD","BK4581","IE00BLSP4239.USD","LU0225284248.USD","BK4599","BK4007","LU0122379950.USD","LU0306806265.USD","LU0170899867.USD","SG9999011175.SGD","IE00BLSP4452.SGD","BK4195","LU0058720904.USD","BK4585","LU0321505868.SGD","BK4533","LU0985481810.HKD","BK4592","LU1066051498.USD","IE00BBT3K403.USD","LU1883839398.USD","SG9999002224.SGD","BK4097","LU0868494617.USD","LU1894683264.USD","LU1066053197.SGD","BK4568"],"gpt_icon":1},{"id":"2510815573","title":"Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2510815573","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510815573?lang=en_us&edition=fundamental","pubTime":"2025-02-11 06:00","pubTimestamp":1739224800,"startTime":"0","endTime":"0","summary":"Enfortumab vedotin plus pembrolizumab continues to demonstrate superior efficacy versus chemotherapy in a broad population, reinforcing the combination as standard of care in first-line treatment of la/mUC. At nearly 30 months of follow-up in the Phase 3 EV-302 trial, the combination doubled median overall survival and progression-free survival compared to chemotherapy, with no new safety signals identified. NEW YORK & TOKYO, February 10, 2025----Pfizer Inc.  and Astellas Pharma Inc.  today announced additional follow-up results from the Phase 3 EV-302 clinical trial  evaluating the efficacy and safety of PADCEV  , a Nectin-4 directed antibody-drug conjugate, plus KEYTRUDA , a PD-1 inhibitor, in patients with previously untreated locally advanced or metastatic urothelial cancer . The results showed a sustained overall survival  and progression-free survival  benefit consistent with the findings of the primary analysis after an additional 12 months of follow-up .1,2 These data will be p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"b68b91779c1270fe944d25cf0021e5aa","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-astellas-padcev-enfortumab-vedotin-220000915.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0321505868.SGD","BK4195","LU1116320737.USD","LU1983299246.USD","ALT","LU0985481810.HKD","LU1929549753.HKD","LU0320765646.SGD","ADC","LU0861579265.USD","LU1585245621.USD","LU1934455277.USD","BK4007","OS","PFE","ALPMF","LU0122379950.USD","AST","MRK","BK4516","BK4559","LU1699723380.USD","LU1037948897.HKD","SG9999013999.USD","LU1934455863.HKD","LU2089984988.USD","LU1162221912.USD","BK4157","PFS","IE0009355771.USD","AEIS","LU1023059063.AUD","LU1571399168.USD","ALPMY","IE00B66KJ199.SGD","LU1057294990.SGD","IE00B2B36J28.USD","LU1883839398.USD","LU1093756168.USD","IE0031619046.USD","BK4097","BK4534","BK4585","LU0234572021.USD","LU0238689110.USD","LU0208291251.USD","IE00BLSP4239.USD","TEN","LU0321505439.SGD","LU0289739699.SGD","BK4080"],"gpt_icon":1},{"id":"2509474462","title":"Astellas Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2509474462","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509474462?lang=en_us&edition=fundamental","pubTime":"2025-02-05 16:59","pubTimestamp":1738745940,"startTime":"0","endTime":"0","summary":"- Ministry of Health, Labour and Welfare to evaluate ACP as potential first and only treatment for patients with geographic atrophy  secondary to age-related macular degeneration  in Japan -. TOKYO, Feb. 5, 2025 /PRNewswire/ -- Astellas Pharma Inc.   today announced the submission of a New Drug Application  to Japan's Ministry of Health, Labour and Welfare  for Conditional Approval of avacincaptad pegol intravitreal solution , a synthetic aptamer that inhibits the complement C5 protein, for the treatment of GA secondary to AMD. If approved, ACP has the potential to become the first and only GA treatment available in Japan.About avacincaptad pegolAvacincaptad pegol  is an investigational drug for treatment of geographic atrophy  secondary to age-related macular degeneration  that has been submitted for Conditional Approval in Japan. ACP is approved in the U.S. as IZERVAY for the treatment of GA secondary to AMD.6 ACP is a synthetic aptamer that inhibits the complement C5 protein.8 Overa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/astellas-submits-drug-application-conditional-085900977.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astellas-submits-drug-application-conditional-085900977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0823421416.USD","BK4575","LU1951198990.SGD","IE00BMPRXN33.USD","LU2054465674.USD","BK4566","LU1303367103.USD","LU0642271901.SGD","LU2264538146.SGD","LU0082616367.USD","LU1989764664.SGD","LU0109392836.USD","LU0823434583.USD","BK4534","LU0979878070.USD","BK4543","LU0127658192.USD","BK4007","ALPMF","BK4512","IE00B5949003.HKD","IE0009356076.USD","LU0198837287.USD","LU2458330243.SGD","BK4141","ACP","ALPMY","LU0056508442.USD","LU1923623000.USD","LU1316542783.SGD","BK4532","BK4573","BK4585","LU0889565833.HKD","LU0823434740.USD","LU2360106780.USD","LU2458330169.SGD","LU2250418816.HKD","LU2098885051.SGD","LU1951200564.SGD","IE00BMPRXR70.SGD","LU1064131342.USD","LU1242518857.USD","LU1242518931.SGD","BK4529","LU0390134368.USD","LU1852331112.SGD","GFS","LU1880398554.USD","IE0004445239.USD"],"gpt_icon":1},{"id":"2508489920","title":"Astellas Makes Announcement about Management Structure","url":"https://stock-news.laohu8.com/highlight/detail?id=2508489920","media":"PR Newswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508489920?lang=en_us&edition=fundamental","pubTime":"2025-02-04 14:30","pubTimestamp":1738650600,"startTime":"0","endTime":"0","summary":"TOKYO, Feb. 4, 2025 /PRNewswire/ -- Astellas Pharma Inc.  today announced thatthe following changes to its management structure effective April 1, 2025.Regarding the Changes in Management StructureAstellas aims to create and deliver \"VALUE\" for patients. To promote drug discovery activities swiftly and efficiently from the early stages of research through to commercialization with patient-centric approach, Astellaswill change itsmanagement structure effective April 1, 2025, establishing new top management positions and making personnel changes as follows.Establishment and Appointment of Chief Research & Development Officer As an innovation engine, we will integrate the research and development teams, and the Primary Focus Leads to provide the next-generation groundbreaking therapies from Astellas. Effective April 1, 2025, we will establish the position of CRDO, overseeing these divisions, with Tadaaki Taniguchi, M.D., Ph.D., the current Chief Medical Officer , appointed to this role.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/astellas-makes-announcement-management-structure-063000131.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astellas-makes-announcement-management-structure-063000131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALPMY","LU1718418525.SGD","LU0061475181.USD","LU0985481810.HKD","LU1074936037.SGD","LU1868836757.USD","LU1861215975.USD","LU0237698245.USD","LU0306807586.USD","LU2133065610.SGD","LU1670710661.SGD","LU1989771016.USD","IE00BJJMRZ35.SGD","LU2294711713.HKD","IE00BFTCPJ56.SGD","ALPMF","LU0882574055.USD","LU1571399168.USD","LU0823414478.USD","CMO","LU2242652126.USD","LU1430594728.SGD","LU0823414551.USD","LU2360032135.SGD","BK4559","LU1868837300.USD","LU2125154935.USD","CEO","LU0306806265.USD","CFO","LU2360107168.USD","BK4534","CCO","BMY","LU0096364046.USD","LU2290526834.HKD","LU0456855351.SGD","LU1093756168.USD","BK4007","LU0868494617.USD","BK4581","LU1093756325.SGD","LU0114720955.EUR","BK4588","LU1323610961.USD","LU1670710588.SGD","LU1868836914.USD","LU2506951792.HKD","LU2357125470.USD","LU1585245621.USD"],"gpt_icon":1},{"id":"2506737571","title":"Bernstein Remains a Buy on Astellas Pharma (ALPMF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2506737571","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506737571?lang=en_us&edition=fundamental","pubTime":"2025-01-27 19:58","pubTimestamp":1737979096,"startTime":"0","endTime":"0","summary":"Bernstein analyst Miki Sogi maintained a Buy rating on Astellas Pharma (ALPMF – Research Report) today and set a price target of Yen2,100.00. The c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bernstein-remains-a-buy-on-astellas-pharma-alpmf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bernstein-remains-a-buy-on-astellas-pharma-alpmf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALPMF","BK4007"],"gpt_icon":0},{"id":"2505859268","title":"Jefferies Reaffirms Their Hold Rating on Astellas Pharma (ALPMF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2505859268","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505859268?lang=en_us&edition=fundamental","pubTime":"2025-01-24 20:16","pubTimestamp":1737720973,"startTime":"0","endTime":"0","summary":"Jefferies analyst Stephen Barker maintained a Hold rating on Astellas Pharma (ALPMF – Research Report) yesterday and set a price target of Yen1,700...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-reaffirms-their-hold-rating-on-astellas-pharma-alpmf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-reaffirms-their-hold-rating-on-astellas-pharma-alpmf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALPMF"],"gpt_icon":0},{"id":"2504407022","title":"Bernstein Sticks to Their Buy Rating for Astellas Pharma (ALPMF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2504407022","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504407022?lang=en_us&edition=fundamental","pubTime":"2025-01-20 21:05","pubTimestamp":1737378348,"startTime":"0","endTime":"0","summary":"In a report released today, Miki Sogi from Bernstein maintained a Buy rating on Astellas Pharma (ALPMF – Research Report), with a price target of Y...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bernstein-sticks-to-their-buy-rating-for-astellas-pharma-alpmf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bernstein-sticks-to-their-buy-rating-for-astellas-pharma-alpmf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALPMF"],"gpt_icon":0},{"id":"2502870400","title":"U.S. FDA Confirms Class 1 Resubmission of the Supplemental New Drug Application for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2502870400","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502870400?lang=en_us&edition=fundamental","pubTime":"2025-01-09 07:30","pubTimestamp":1736379000,"startTime":"0","endTime":"0","summary":"TOKYO, Jan. 8, 2025 /PRNewswire/ -- Astellas Pharma Inc.  today announced the U.S. Food and Drug Administration  accepted the revised supplemental New Drug Application  for IZERVAY  for the treatment of geographic atrophy  secondary to age-related macular degeneration  on January 6, 2025, in response to the Agency's November 2024Complete Response Letter . The application was refiled following a December 20, 2024, meeting between the FDA and Astellas and has been designated as a Class 1 resubmission, with a 60-day review period.IZERVAY was approved by the U.S. Food and Drug Administration on August 4, 2023, for the treatment of GA secondary to AMD.The sNDA seeks to add positive 2-year data to the IZERVAY U.S. Prescribing Information based on results from the GATHER2 Phase 3 clinical trial.The impact of this matteron Astellas' financial results for the fiscal year ending March 31, 2025, is expected to be minor.IZERVAY  is a prescription eye injection, used to treat geographic atrophy , t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/u-fda-confirms-class-1-233000210.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/u-fda-confirms-class-1-233000210.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4121","LU1951198990.SGD","LU0823434583.USD","BK4530","IE0009356076.USD","LU2250418816.HKD","LU1316542783.SGD","CRL","LU0081259029.USD","LU2458330169.SGD","IE0004445239.USD","IE00B5949003.HKD","IE00BMPRXN33.USD","BK4588","BK4566","GFS","LU0823421333.USD","LU2458330243.SGD","ALPMY","LU1803068979.SGD","LU2054465674.USD","LU0642271901.SGD","LU1242518857.USD","LU1951200564.SGD","LU2098885051.SGD","BK4141","LU2264538146.SGD","BK4512","LU1989764664.SGD","BK4534","LU0082616367.USD","BK4573","BK4529","LU0390134368.USD","LU0127658192.USD","LU1880398554.USD","LU1064131342.USD","LU1303367103.USD","BK4007","ALPMF","LU1923623000.USD","BK4575","LU0198837287.USD","LU1242518931.SGD","LU0823421416.USD","ACP","LU0823434740.USD","LU0719512351.SGD","LU1988902786.USD","LU0979878070.USD"],"gpt_icon":1},{"id":"2501742284","title":"China's National Medical Products Administration (NMPA) Approves PADCEV™ in combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2501742284","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501742284?lang=en_us&edition=fundamental","pubTime":"2025-01-08 17:55","pubTimestamp":1736330100,"startTime":"0","endTime":"0","summary":"- First regimen to be approved in China to demonstrate superiority to platinum-containing chemotherapy for the treatment of locally advanced or metastatic urothelial cancer, the standard of care for nearly 40 years1. - NMPA approval based on the global Phase 3 EV-302 trial  where the treatment combination significantly improved overall survival and progression-free survival outcomes1. TOKYO, Jan. 8, 2025 /PRNewswire/ -- Astellas Pharma Inc.  today announced that China's National Medical Products Administration  has approved PADCEV in combination with KEYTRUDA  for adult patients with locally advanced or metastatic urothelial cancer . The treatment combination willprovide a new therapeutic option to patients with la/mUC in Chinaand offer an alternative to platinum-containing chemotherapy, the standard of care for nearly 40 years.1. Professor Huang Jian, Lead Primary Investigator of the EV-302 Study in China, Chairman of the Urology Subcommittee of the Chinese Medical Association, Depart","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/chinas-national-medical-products-administration-095500525.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chinas-national-medical-products-administration-095500525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1244550577.SGD","PFS","SG9999001176.SGD","PFE","LU1093756168.USD","SG9999014542.SGD","ALPMY","IE00BVYPNV92.GBP","BK4579","LU0265550359.USD","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","BK4599","IE00BFMHRM44.USD","SG9999001440.SGD","OS","LU2112291526.USD","IE0002141913.USD","BK4097","CSCO","LU1037948897.HKD","BK4550","ALPMF","LU2237443382.USD","IE00B3PB1722.GBP","SG9999014567.USD","LU0203345920.USD","LU1066051811.HKD","SG9999003800.SGD","LU1291159041.SGD","LU2361044865.SGD","MRK","IE0009355771.USD","LU0950375773.USD","LU0985481810.HKD","NHLD","ADC","LU1894683264.USD","AEIS","LU0320765489.SGD","LU1989772923.USD","SG9999015341.SGD","LU0306807586.USD","LU0321505439.SGD","LU0942090050.USD","LU1917777945.USD","LU0965509101.SGD","LU0965509010.AUD","LU0306806265.USD","LU2506952097.USD","LU1941712348.USD"],"gpt_icon":1},{"id":"2489345456","title":"Astellas and Dr. Jen Ashton launch \"Cooler Moments\" to Spotlight Menopausal Hot Flashes and Empower Women to Advocate for Themselves","url":"https://stock-news.laohu8.com/highlight/detail?id=2489345456","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489345456?lang=en_us&edition=fundamental","pubTime":"2024-12-05 21:49","pubTimestamp":1733406540,"startTime":"0","endTime":"0","summary":"\"Cooler Moments\" educates and empowers women in midlife to speak up for themselves and celebrate this natural change in their lives.Dr. Jen Ashton, Board-Certified OBGYN, Former Chief Medical Correspondent\"I'm honored to partner with Astellas to help inspire conversation about hot flashes and night sweats due to menopause and treatment options. Managing these symptoms is not one-size-fits-all, and women should feel comfortable having an open dialogue with their healthcare providers to create a plan that's right for them. As a doctor, I've seen how hot flashes due to menopause can significantly impact women, and I know how important it is women are counseled about all of their options, both hormonal and nonhormonal.2Many women and doctors alike may not know that there are nonhormonal treatment options such as VEOZAH available, especially for women who cannot or choose not to take hormon","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/mDzIeKJE_9jXg01gnDqnnQ--~B/aD0xODAwO3c9MjcwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/90cfe5e096dcfdc59723a8c260860bb5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/mDzIeKJE_9jXg01gnDqnnQ--~B/aD0xODAwO3c9MjcwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/90cfe5e096dcfdc59723a8c260860bb5"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/astellas-dr-jen-ashton-launch-134900879.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astellas-dr-jen-ashton-launch-134900879.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALPMY","BK4007","EMPW.U","ALPMF"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALPMF\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-04-25","symbol":"ALPMF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1714017600000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-02-05","symbol":"ALPMF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1707109200000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2023-11-01","symbol":"ALPMF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1698811200000,"reportTimeType":"","actualEps":null},{"date":"2023-09-28","symbol":"ALPMF","amount":35,"announcedDate":"2023-07-19","type":"dividend","market":"US","newRecordDate":"2023-09-30","defaultRemindTime":1695907800000,"name":"Astellas Pharma, Inc.","recordDate":"2023-12-01","payableDate":"2023-09-30","currency":"JPY","dateTimestamp":1695873600000,"payDate":"2023-12-01"},{"market":"US","date":"2023-08-01","symbol":"ALPMF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1690862400000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALPMF\",market:\"US\",,,undefined,":[{"executeDate":"2019-03-27","recordDate":"2019-03-31","paymentDate":"2019-06-18","value":19,"currency":"JPY"},{"executeDate":"2019-09-27","recordDate":"2019-09-30","paymentDate":"2019-12-03","value":20,"currency":"JPY"},{"executeDate":"2020-03-30","recordDate":"2020-03-31","paymentDate":"2020-06-19","value":20,"currency":"JPY"},{"executeDate":"2020-09-29","recordDate":"2020-09-30","paymentDate":"2020-12-01","value":21,"currency":"JPY"},{"executeDate":"2021-03-30","recordDate":"2021-03-31","paymentDate":"2021-06-01","value":21,"currency":"JPY"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALPMF\",market:\"US\",delay:false,,,undefined,":{}}}